{"entity":{"type":"insider","cik":"0001929354","url":"/insider/0001929354","json_url":"/insider/0001929354.json","name":"Caissa Capital Management ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":34,"n_filings":14,"first":"2023-04-11","last":"2023-06-27","span_basis":"filed_date"},"name_variants":[{"name":"Caissa Capital Management ltd.","source":"filing","n_filings":14,"first_seen":"2023-04-11","last_seen":"2023-06-27"}],"transactions":[{"id":8246126,"accession":"0001929354-23-000016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000016","line_url":"/filing/0001929354-23-000016","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1608000.0,"shares_display":"1,608,000","price_per_share":0.6406584639303483,"price_display":"0.64","price_state":"stated","total_value":1030178.81,"total_display":"1,030,178.81","total_whole":"1,030,179","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-26","filed_date":"2023-06-27","scope":"insider","n_lines":2},{"id":8739115,"accession":"0001929354-23-000015","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000015","line_url":"/filing/0001929354-23-000015#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":4.1444,"price_display":"4.14","price_state":"stated","total_value":8288.8,"total_display":"8,288.80","total_whole":"8,289","shares_owned_after":1425700.0,"shares_owned_after_display":"1,425,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-20","filed_date":"2023-06-20","scope":"insider"},{"id":8739113,"accession":"0001929354-23-000015","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000015","line_url":"/filing/0001929354-23-000015#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":3.9048,"price_display":"3.90","price_state":"stated","total_value":11714.4,"total_display":"11,714.40","total_whole":"11,714","shares_owned_after":1423700.0,"shares_owned_after_display":"1,423,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-16","filed_date":"2023-06-20","scope":"insider"},{"id":8739110,"accession":"0001929354-23-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000015","line_url":"/filing/0001929354-23-000015#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3160.0,"shares_display":"3,160","price_per_share":3.6837,"price_display":"3.68","price_state":"stated","total_value":11640.492,"total_display":"11,640.49","total_whole":"11,640","shares_owned_after":1420700.0,"shares_owned_after_display":"1,420,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-15","filed_date":"2023-06-20","scope":"insider"},{"id":7912377,"accession":"0001929354-23-000014","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000014","line_url":"/filing/0001929354-23-000014#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000.0,"shares_display":"6,000","price_per_share":3.479,"price_display":"3.48","price_state":"stated","total_value":20874.0,"total_display":"20,874.00","total_whole":"20,874","shares_owned_after":1417540.0,"shares_owned_after_display":"1,417,540","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-14","filed_date":"2023-06-14","scope":"insider"},{"id":7912373,"accession":"0001929354-23-000014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000014","line_url":"/filing/0001929354-23-000014#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8750.0,"shares_display":"8,750","price_per_share":3.8216,"price_display":"3.82","price_state":"stated","total_value":33439.0,"total_display":"33,439.00","total_whole":"33,439","shares_owned_after":1411540.0,"shares_owned_after_display":"1,411,540","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-14","scope":"insider"},{"id":7912370,"accession":"0001929354-23-000014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000014","line_url":"/filing/0001929354-23-000014#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2149.0,"shares_display":"2,149","price_per_share":4.3352,"price_display":"4.34","price_state":"stated","total_value":9316.3448,"total_display":"9,316.34","total_whole":"9,316","shares_owned_after":1402790.0,"shares_owned_after_display":"1,402,790","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-12","filed_date":"2023-06-14","scope":"insider"},{"id":8030207,"accession":"0001929354-23-000013","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000013","line_url":"/filing/0001929354-23-000013#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5044.0,"shares_display":"5,044","price_per_share":4.1427,"price_display":"4.14","price_state":"stated","total_value":20895.7788,"total_display":"20,895.78","total_whole":"20,896","shares_owned_after":1400641.0,"shares_owned_after_display":"1,400,641","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-09","filed_date":"2023-06-09","scope":"insider"},{"id":8030204,"accession":"0001929354-23-000013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000013","line_url":"/filing/0001929354-23-000013#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6398.0,"shares_display":"6,398","price_per_share":3.9271,"price_display":"3.93","price_state":"stated","total_value":25125.5858,"total_display":"25,125.59","total_whole":"25,126","shares_owned_after":1395597.0,"shares_owned_after_display":"1,395,597","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-08","filed_date":"2023-06-09","scope":"insider"},{"id":8030201,"accession":"0001929354-23-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000013","line_url":"/filing/0001929354-23-000013#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2984.0,"shares_display":"2,984","price_per_share":3.4914,"price_display":"3.49","price_state":"stated","total_value":10418.3376,"total_display":"10,418.34","total_whole":"10,418","shares_owned_after":1389199.0,"shares_owned_after_display":"1,389,199","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-07","filed_date":"2023-06-09","scope":"insider"},{"id":8664032,"accession":"0001929354-23-000012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000012","line_url":"/filing/0001929354-23-000012#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":844.0,"shares_display":"844","price_per_share":2.87,"price_display":"2.87","price_state":"stated","total_value":2422.28,"total_display":"2,422.28","total_whole":"2,422","shares_owned_after":1386215.0,"shares_owned_after_display":"1,386,215","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-31","filed_date":"2023-06-02","scope":"insider"},{"id":7901034,"accession":"0001929354-23-000011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000011","line_url":"/filing/0001929354-23-000011#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":671.0,"shares_display":"671","price_per_share":2.867,"price_display":"2.87","price_state":"stated","total_value":1923.757,"total_display":"1,923.76","total_whole":"1,924","shares_owned_after":1385371.0,"shares_owned_after_display":"1,385,371","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-30","filed_date":"2023-05-30","scope":"insider"},{"id":7901031,"accession":"0001929354-23-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000011","line_url":"/filing/0001929354-23-000011#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":2.77,"price_display":"2.77","price_state":"stated","total_value":5540.0,"total_display":"5,540.00","total_whole":"5,540","shares_owned_after":1384700.0,"shares_owned_after_display":"1,384,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-30","scope":"insider"},{"id":8642055,"accession":"0001929354-23-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000010","line_url":"/filing/0001929354-23-000010","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9000.0,"shares_display":"9,000","price_per_share":2.979605,"price_display":"2.98","price_state":"stated","total_value":26816.445,"total_display":"26,816.44","total_whole":"26,816","shares_owned_after":1382700.0,"shares_owned_after_display":"1,382,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-24","filed_date":"2023-05-24","scope":"insider","n_lines":2},{"id":8090340,"accession":"0001929354-23-000009","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000009","line_url":"/filing/0001929354-23-000009#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7000.0,"shares_display":"7,000","price_per_share":3.3368,"price_display":"3.34","price_state":"stated","total_value":23357.6,"total_display":"23,357.60","total_whole":"23,358","shares_owned_after":1373700.0,"shares_owned_after_display":"1,373,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-22","filed_date":"2023-05-22","scope":"insider"},{"id":8090338,"accession":"0001929354-23-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000009","line_url":"/filing/0001929354-23-000009#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6500.0,"shares_display":"6,500","price_per_share":3.5157,"price_display":"3.52","price_state":"stated","total_value":22852.05,"total_display":"22,852.05","total_whole":"22,852","shares_owned_after":1366700.0,"shares_owned_after_display":"1,366,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-19","filed_date":"2023-05-22","scope":"insider"},{"id":8090336,"accession":"0001929354-23-000009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000009","line_url":"/filing/0001929354-23-000009#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13121.0,"shares_display":"13,121","price_per_share":3.2896,"price_display":"3.29","price_state":"stated","total_value":43162.8416,"total_display":"43,162.84","total_whole":"43,163","shares_owned_after":1360200.0,"shares_owned_after_display":"1,360,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-18","filed_date":"2023-05-22","scope":"insider"},{"id":8595799,"accession":"0001929354-23-000008","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000008","line_url":"/filing/0001929354-23-000008#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":379.0,"shares_display":"379","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":1042.25,"total_display":"1,042.25","total_whole":"1,042","shares_owned_after":1347079.0,"shares_owned_after_display":"1,347,079","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-16","filed_date":"2023-05-16","scope":"insider"},{"id":8595796,"accession":"0001929354-23-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000008","line_url":"/filing/0001929354-23-000008#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1715.0,"shares_display":"1,715","price_per_share":2.5459,"price_display":"2.55","price_state":"stated","total_value":4366.2185,"total_display":"4,366.22","total_whole":"4,366","shares_owned_after":1346700.0,"shares_owned_after_display":"1,346,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-16","scope":"insider"},{"id":8595792,"accession":"0001929354-23-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000008","line_url":"/filing/0001929354-23-000008#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2285.0,"shares_display":"2,285","price_per_share":2.45,"price_display":"2.45","price_state":"stated","total_value":5598.25,"total_display":"5,598.25","total_whole":"5,598","shares_owned_after":1344985.0,"shares_owned_after_display":"1,344,985","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-12","filed_date":"2023-05-16","scope":"insider"},{"id":8307955,"accession":"0001929354-23-000007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000007","line_url":"/filing/0001929354-23-000007#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.6216,"price_display":"2.62","price_state":"stated","total_value":13108.0,"total_display":"13,108.00","total_whole":"13,108","shares_owned_after":1342700.0,"shares_owned_after_display":"1,342,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-08","filed_date":"2023-05-08","scope":"insider"},{"id":8307953,"accession":"0001929354-23-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000007","line_url":"/filing/0001929354-23-000007#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.875,"price_display":"2.88","price_state":"stated","total_value":14375.0,"total_display":"14,375.00","total_whole":"14,375","shares_owned_after":1337700.0,"shares_owned_after_display":"1,337,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-05","filed_date":"2023-05-08","scope":"insider"},{"id":8307950,"accession":"0001929354-23-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000007","line_url":"/filing/0001929354-23-000007#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":2.7921,"price_display":"2.79","price_state":"stated","total_value":41881.5,"total_display":"41,881.50","total_whole":"41,882","shares_owned_after":1332700.0,"shares_owned_after_display":"1,332,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-04","filed_date":"2023-05-08","scope":"insider"},{"id":8758618,"accession":"0001929354-23-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001929354-23-000006","line_url":"/filing/0001929354-23-000006#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1504.0,"shares_display":"1,504","price_per_share":2.96,"price_display":"2.96","price_state":"stated","total_value":4451.84,"total_display":"4,451.84","total_whole":"4,452","shares_owned_after":1317700.0,"shares_owned_after_display":"1,317,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-27","filed_date":"2023-04-27","scope":"insider"},{"id":8758615,"accession":"0001929354-23-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000006","line_url":"/filing/0001929354-23-000006#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":425.0,"shares_display":"425","price_per_share":2.97,"price_display":"2.97","price_state":"stated","total_value":1262.25,"total_display":"1,262.25","total_whole":"1,262","shares_owned_after":1316196.0,"shares_owned_after_display":"1,316,196","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-26","filed_date":"2023-04-27","scope":"insider"},{"id":8758612,"accession":"0001929354-23-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000006","line_url":"/filing/0001929354-23-000006#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5571.0,"shares_display":"5,571","price_per_share":2.9993,"price_display":"3.00","price_state":"stated","total_value":16709.1003,"total_display":"16,709.10","total_whole":"16,709","shares_owned_after":1315771.0,"shares_owned_after_display":"1,315,771","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-25","filed_date":"2023-04-27","scope":"insider"},{"id":7912367,"accession":"0001929354-23-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000005","line_url":"/filing/0001929354-23-000005#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12500.0,"shares_display":"12,500","price_per_share":3.0624,"price_display":"3.06","price_state":"stated","total_value":38280.0,"total_display":"38,280.00","total_whole":"38,280","shares_owned_after":1310200.0,"shares_owned_after_display":"1,310,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-24","filed_date":"2023-04-24","scope":"insider"},{"id":7912364,"accession":"0001929354-23-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000005","line_url":"/filing/0001929354-23-000005#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.0783,"price_display":"3.08","price_state":"stated","total_value":15391.5,"total_display":"15,391.50","total_whole":"15,392","shares_owned_after":1297700.0,"shares_owned_after_display":"1,297,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-20","filed_date":"2023-04-24","scope":"insider"},{"id":7883943,"accession":"0001929354-23-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000003","line_url":"/filing/0001929354-23-000003#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.9438,"price_display":"2.94","price_state":"stated","total_value":29438.0,"total_display":"29,438.00","total_whole":"29,438","shares_owned_after":1292700.0,"shares_owned_after_display":"1,292,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-18","filed_date":"2023-04-18","scope":"insider"},{"id":7883939,"accession":"0001929354-23-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000003","line_url":"/filing/0001929354-23-000003#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":2.9624,"price_display":"2.96","price_state":"stated","total_value":44436.0,"total_display":"44,436.00","total_whole":"44,436","shares_owned_after":1282700.0,"shares_owned_after_display":"1,282,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-17","filed_date":"2023-04-18","scope":"insider"},{"id":8418569,"accession":"0001929354-23-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001929354-23-000002","line_url":"/filing/0001929354-23-000002#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":2.8432,"price_display":"2.84","price_state":"stated","total_value":71080.0,"total_display":"71,080.00","total_whole":"71,080","shares_owned_after":1267700.0,"shares_owned_after_display":"1,267,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-11","filed_date":"2023-04-11","scope":"insider"},{"id":8418564,"accession":"0001929354-23-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001929354-23-000002","line_url":"/filing/0001929354-23-000002#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001929354","owner_name":"Caissa Capital Management ltd.","owner_display_name":"Caissa Capital Management ltd.","owner_url":"/insider/0001929354","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31329.0,"shares_display":"31,329","price_per_share":2.2802,"price_display":"2.28","price_state":"stated","total_value":71436.3858,"total_display":"71,436.39","total_whole":"71,436","shares_owned_after":1242700.0,"shares_owned_after_display":"1,242,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-10","filed_date":"2023-04-11","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":34,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":34,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":34},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001534120","name":"Avalo Therapeutics, Inc.","url":"/issuer/0001534120","role":"Ten percent owner","n_filings":14,"first_seen":"2023-04-11","last_seen":"2023-06-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001929354","retrieved_at":"2026-08-26T01:44:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}